Jay S. Duker, M.D. is an Adjunct Professor of Ophthalmology at the Tufts Medical Center and Tufts University School of Medicine in Boston, Massachusetts. He served as the Chair of the Ophthalmology Department at Tufts between 2001 and 2021.
Through his varied ophthalmology-related activities spanning four decades of practice, he has developed a local, regional, national, and international reputation as a highly successful clinician, surgeon, diagnostician, educator, researcher, administrator, and entrepreneur.
Dr. Duker’s part-time clinical practice is limited to medical diseases of the posterior segment of the eye including age-related macular degeneration (AMD), diabetic retinopathy, retinal vascular diseases, posterior segment uveitis, and intraocular tumors. He has a particular interest in rare and unusual retinal disorders, especially those connected to systemic disease.
Novel imaging techniques of the eye, especially optical coherence tomography (OCT), drug delivery to the posterior segment, retinal vascular disorders and posterior segment uveitis. Over the past two decades, Dr. Duker has been instrumental in discovering clinical applications of OCT technology.
Vitreoretinal Diseases and Surgery and Intraocular Tumors, Wills Eye Hospital
Wills Eye Hospital
Jefferson Medical College of Thomas Jefferson University
Adjunct Professor of Ophthalmology, Tufts University School of Medicine
American Board of Ophthalmology
Professional Honors and Awards
1992 – American Academy of Ophthalmology, Honor Award
2003 – American Academy of Ophthalmology, Senior Achievement Award
2010 – American Society of Retina Specialists, Honor Award
2013 – American Society of Retina Specialists, Senior Honor Award
2015 – American Academy of Ophthalmology, Life Achievement Honor Award
2015 – Brazilian Society of Retina and Vitreous Honor Award
2019 – Viki and Jack Farber Vision Research Award, Wills Eye Hospital
Dr. Duker’s current full time position is Chief Operating Officer (COO) of EyePoint Pharmaceuticals, a publicly traded biotech company that specializes in long term drug delivery to the eye. Dr. Duker is the founder of several successful businesses including the fifth busiest independent ophthalmic ambulatory surgery center in the United States, SurgiSite Boston. Dr. Duker is a founder of Hemera Biosciences, a clinical-stage biotech company developing treatments of eye disease through complement inhibition using a gene therapy delivery system that was acquired by Janssen in 2020, and the Boston Image Reading Center (BIRC).
American Medical Association
American Academy of Ophthalmology
Massachusetts Society of Eye Physicians and Surgeons
Massachusetts Medical Society
FRAME Fluorescein Angiography Club
International Academy of Sports Vision
American Society of Retina Specialists
New England Ophthalmology Society
Association of University Professors in Ophthalmology
Principal Founder and Director, SurgiSite Boston
Director and Founder, Hemera Biosciences
Director and Chair of the Board, Sesen Bio
Director, EyePoint Pharma
Founding Editor-in-Chief, International Journal of Retina and Vitreous
Editorial Board of OSLI Retina, Retina Cases and Brief Reports, and Investigative Ophthalmology and Visual Sciences
Books and chapters
Yanoff M, Duker JS, eds. Ophthalmology. Mosby, London, 4 Editions from 1999-2014.
Duker JS, Waheed NK, Goldman DR. Handbook of Retinal OCT. Elsevier, Saunders, 2014.
Duker JS, Witkin AJ, eds. Age-Related Macular Degeneration – Current Management.
Slack Incorporated, NJ, 2015.
Laver N V, Sitko K, Duker JS, Farhat NA. Ocular Tumors. In: Linda M. McManus, Richard N. Mitchell, editors. Pathobiology of Human Disease. San Diego: Elsevier; 2014. P. 2179-2200.
Dr. Duker has over 250 papers published in peer-reviewed journals. His manuscripts have appeared in high impact journals and one of them has been among the top 10 referenced ophthalmology research papers over the past five years. Here are a few recent examples:
Duker JS, Kaiser PK, Binder S, de Smet MD, Gaudric A, Reichel E, Sadda SR, Sebag J, Spaide RF, Stalmans P. The International Vitreomacular Traction Study Group Classification of Vitreomacular Adhesion, Traction, and Macular Hole. Ophthalmology. Dec 2013;120(12):2611-9.
Duker JS, Moshfeghi AA. Ocriplasmin: A Medical or Surgical Therapy? Retina. Nov/Dec 2013;33(10):2001-2.
Lally DR, Duker JS, Mignano JE, Martin S, Witkin AJ. Regression of Choroidal Metastasis from Breast Carcinoma Treated with Gamma Knife Radiosurgery. JAMA Ophthalmology. October 2014;132(10):1248-1249.
Fein JG, Branchini LA, Manjunath V, Regatieri CV, Fujimoto JG, Duker JS. Analysis of Short-Term Change in Subfoveal Choroidal Thickness in Eyes with Age-Related Macular Degeneration using Optical Coherence Tomography. OSLI Retina. Jan/Feb 2014;45(1):32-7.
Mehta M, Rasheed RA, Duker JS, Reichel E, Feinberg E, Husain D, Foster CS, Laver NV. Vitreous Evaluation: A Diagnostic Challenge. Ophthalmology. Mar 2015;122(3):531-7.
Inoue M, Jung JJ, Balaratnasingam C, Dansingani KK, Dhrami-Gavazi E, Suzuki M, de Carlo TE, Shahlaee A, Klufas MA, El Maftouhi A, Duker JS, Ho AC, Quaranta-El Maftouhi M, Sarraf D, Freund KB, COFT-1 Study Group. A Comparison Between Optical Coherence Tomography Angiography and Fluorescein Angiography for the Imaging of Type 1 Neovascularization. IOVS. July 2016;57:314-23.
Dr. Duker’s Office: 617-636-4604
Patient Appointments: Boston: 617-636-4604